Efficacy Analysis of Baduanjin Combined with Rabeprazole in Refractory Gastroesophageal Reflux Disease
Objective:To study the role of Baduanjin+rabeprazole in the treatment of refractory gastroesophageal reflux disease.Methods:60 patients with refractory gastroesophageal reflux disease in from December 2021 to July 2023 were divided into control group(rebeprazole alone)and treatment group(BaduanJin+rebeprazole).First tolerance scale(RDQ)score,self-measurement of gastroesophageal reflux disease(Gerd Q)score,efficacy,quality of life scale(SF-36)score,and Chinese medicine syndrome score of two groups were compared.Results:After treatment,RDQ score,Gerd Q score and TCM syndrome score in treatment group were lower than those in control group,and quality of life score was higher than those in control group,with statistically significant difference(t=2.583,0.001,13.562,20.210,9.509,57.103,15.137,4.912,4.185,8.269;P＜0.05).The total effective rate of treatment group was higher than that of control group,and the difference was statistically significant(x2＝6.667,P＜0.05).Conclusion:Baduanjin+leprazole has achieved an ideal effect in the treatment of refractory gastroesophageal reflux disease,which significantly alleviates the symptoms of patients,promotes the total efficiency of treatment,and improves the quality of life of patients after treatment.
BaduanjinRebeprazoleRefractory gastroesophageal reflux diseaseQuality of life
万方数据
维普
